Prospects for new lung cancer treatments that target EMT signaling

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Lung cancer is the most common cancer worldwide. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, molecularly targeted therapy including epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors, and immunotherapy. These treatments can be administered alone or in combination. Despite therapeutic advances, however, lung cancer remains the leading cause of cancer death. Recent studies have indicated that epithelial-mesenchymal transition (EMT) is associated with malignancy in various types of cancer, and activation of EMT signaling in cancer cells is widely considered to contribute to metastasis, recurrence, or therapeutic resistance. In this review, we provide an overview of the role of EMT in the progression of lung cancer. We also discuss the prospects for new therapeutic strategies that target EMT signaling in lung cancer. Developmental Dynamics 247:462–472, 2018.

Original languageEnglish
Pages (from-to)462-472
Number of pages11
JournalDevelopmental Dynamics
Volume247
Issue number3
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Epithelial-Mesenchymal Transition
Lung Neoplasms
Neoplasms
Therapeutics
Epidermal Growth Factor Receptor
Immunotherapy
Cause of Death
Radiotherapy
Neoplasm Metastasis
Recurrence
Drug Therapy

Keywords

  • drug resistance
  • epithelial-mesenchymal transition
  • lung disease
  • ZEB1

ASJC Scopus subject areas

  • Developmental Biology

Cite this

Prospects for new lung cancer treatments that target EMT signaling. / Otsuki, Yuji; Saya, Hideyuki; Arima, Yoshimi.

In: Developmental Dynamics, Vol. 247, No. 3, 01.03.2018, p. 462-472.

Research output: Contribution to journalReview article

@article{090e097feca442bc827c2a139ec4a302,
title = "Prospects for new lung cancer treatments that target EMT signaling",
abstract = "Lung cancer is the most common cancer worldwide. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, molecularly targeted therapy including epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors, and immunotherapy. These treatments can be administered alone or in combination. Despite therapeutic advances, however, lung cancer remains the leading cause of cancer death. Recent studies have indicated that epithelial-mesenchymal transition (EMT) is associated with malignancy in various types of cancer, and activation of EMT signaling in cancer cells is widely considered to contribute to metastasis, recurrence, or therapeutic resistance. In this review, we provide an overview of the role of EMT in the progression of lung cancer. We also discuss the prospects for new therapeutic strategies that target EMT signaling in lung cancer. Developmental Dynamics 247:462–472, 2018.",
keywords = "drug resistance, epithelial-mesenchymal transition, lung disease, ZEB1",
author = "Yuji Otsuki and Hideyuki Saya and Yoshimi Arima",
year = "2018",
month = "3",
day = "1",
doi = "10.1002/dvdy.24596",
language = "English",
volume = "247",
pages = "462--472",
journal = "Developmental Dynamics",
issn = "1058-8388",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Prospects for new lung cancer treatments that target EMT signaling

AU - Otsuki, Yuji

AU - Saya, Hideyuki

AU - Arima, Yoshimi

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Lung cancer is the most common cancer worldwide. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, molecularly targeted therapy including epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors, and immunotherapy. These treatments can be administered alone or in combination. Despite therapeutic advances, however, lung cancer remains the leading cause of cancer death. Recent studies have indicated that epithelial-mesenchymal transition (EMT) is associated with malignancy in various types of cancer, and activation of EMT signaling in cancer cells is widely considered to contribute to metastasis, recurrence, or therapeutic resistance. In this review, we provide an overview of the role of EMT in the progression of lung cancer. We also discuss the prospects for new therapeutic strategies that target EMT signaling in lung cancer. Developmental Dynamics 247:462–472, 2018.

AB - Lung cancer is the most common cancer worldwide. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, molecularly targeted therapy including epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors, and immunotherapy. These treatments can be administered alone or in combination. Despite therapeutic advances, however, lung cancer remains the leading cause of cancer death. Recent studies have indicated that epithelial-mesenchymal transition (EMT) is associated with malignancy in various types of cancer, and activation of EMT signaling in cancer cells is widely considered to contribute to metastasis, recurrence, or therapeutic resistance. In this review, we provide an overview of the role of EMT in the progression of lung cancer. We also discuss the prospects for new therapeutic strategies that target EMT signaling in lung cancer. Developmental Dynamics 247:462–472, 2018.

KW - drug resistance

KW - epithelial-mesenchymal transition

KW - lung disease

KW - ZEB1

UR - http://www.scopus.com/inward/record.url?scp=85042131564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042131564&partnerID=8YFLogxK

U2 - 10.1002/dvdy.24596

DO - 10.1002/dvdy.24596

M3 - Review article

C2 - 28960588

AN - SCOPUS:85042131564

VL - 247

SP - 462

EP - 472

JO - Developmental Dynamics

JF - Developmental Dynamics

SN - 1058-8388

IS - 3

ER -